Intelligence · Clinical Development
Pipeline search results
Programs matching “azacitidine” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 25 pipeline programs matching "azacitidine" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
APR-246 + azacitidine
Aprea Therapeutics
MDS
1 trial -
Azacitidine
Takeda
Myelodysplastic Syndrome
1 trial -
Azacitidine Combined With Venetoclax and ATRA group
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
AZACITIDINE
ALX ONCOLOGY HOLDINGS INC
Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease
1 trial -
AZACITIDINE
Blueprint Medicines (Netherlands) B.V.
Advanced Systemic Mastocytosis
1 trial -
Azacitidine
Janssen Cilag International NV
Myelodysplastic Syndromes
1 trial -
Azacitidine
The First People's Hospital of Lianyungang
Philadelphia Chromosome
1 trial -
Azacitidine
Takeda
Myelodysplastic Syndromes
2 trials -
Azacitidine
Syndax Pharmaceuticals
Non-Small Cell Lung Cancer
1 trial -
Azacitidine (AZA) with Ruxolitinib
The First People's Hospital of Lianyungang
MDS/MPN
1 trial -
Azacitidine Injection
The First People's Hospital of Lianyungang
B Acute Lymphoblastic Leukemia
1 trial -
Azacitidine in Combination With Venetoclax
The First People's Hospital of Lianyungang
Hematologic Malignancy
1 trial -
CHOP+selinexor+5-Azacitidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral T Cell Lymphoma
1 trial -
IIT2024067
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML
1 trial -
IIT2024097
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML (Acute Myelogenous Leukemia)
1 trial -
Ivosidenib combined with venetoclax and azacitidine
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
SY-1425, AZACITIDINE
Lacuna Pharma Pty Ltd
Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS)
1 trial -
Venetoclax, Azacitidine
The First People's Hospital of Lianyungang
T-cell Acute Lymphoblastic Leukemia
1 trial -
Venetoclax, Azacitidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial -
Venetoclax；Azacitidine；Homoharringtonine
The First People's Hospital of Lianyungang
Secondary Acute Myeloid Leukemia
1 trial -
XMDYYYXYK-04
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
mitoxantrone liposome 16 and azacitidine
NovaBridge Biosciences
Angioimmunoblastic T-cell Lymphoma
1 trial -
APR-548 + Azacitidine
Aprea Therapeutics
MDS
1 trial -
Azacitidine
PMV Pharmaceuticals
Myelodysplastic Syndrome
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.